Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Evidence on Tap - Expedited Knowledge Synthesis

Unity Health Toronto

$99,300.00

Systematic reviews of the evidence that tests for chronic cerebrospinal venous insufficiency (CCSVI) are valid and reproducible, that CCSVI is associated with multiple sclerosis, and of the benefits and harms of endovascular therapy for multiple sclerosis

EF 2011-12

Résumé
Dr. Zamboni from Italy has recently hypothesized that multiple sclerosis (MS) is caused by an abnormality in the veins draining blood from the brain and spinal cord. This abnormality is called chronic cerebrospinal venous insufficiency (CCSVI). Dr. Zamboni has also proposed that treating these abnormalities by either dilating the veins with a balloon or inserting a stent improves the symptoms of MS. Although some people with MS have reported improvement in their symptoms after treatment, this new theory about the cause and treatment of MS is very controversial because the quality of the science underlying it is relatively poor and the results have not been replicated by other groups. However, a number of other groups are now conducting studies, the results of which should be available over the next one to two years. The purpose of this study is to identify and summarize all of the scientific reports about CCSVI, to determine how accurately CCSVI can be diagnosed, whether or not it is more common in people with MS than in people who do not have MS, and the benefits and harms of balloon or stent treatment for CCSVI. We will use rigorous scientific methods to grade the quality of the scientific literature about this topic. We will report our initial findings in May 2011, and every 3 months after that for at least one year. We will present our findings to the CIHR expert panel on CCSVI and MS, will publish our results in scientific journals, and will also produce descriptions of our results written for people with MS, the public and health care decision makers.
Programme
Evidence on Tap - Expedited Knowledge Synthesis
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
252386
Name
Laupacis Andreas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Special Cases
Projecttitle
Systematic reviews of the evidence that tests for chronic cerebrospinal venous insufficiency (CCSVI) are valid and reproducible, that CCSVI is associated with multiple sclerosis, and of the benefits and harms of endovascular therapy for multiple sclerosis
Programtype2
Operating Grants
Orgnameinp2
Unity Health Toronto
Cihramount2
$99,300
Cihrequipment2
$0
Programname2
Evidence on Tap - Expedited Knowledge Synthesis
Keyworddelim
.; Chronic Cerebrospinal Venous Insufficiency; Diagnostic Tests; Doppler Ultrasound; Multiple Sclerosis; Systematic Review; Venography; Venoplasty
Abstract
Dr. Zamboni from Italy has recently hypothesized that multiple sclerosis (MS) is caused by an abnormality in the veins draining blood from the brain and spinal cord. This abnormality is called chronic cerebrospinal venous insufficiency (CCSVI). Dr. Zamboni has also proposed that treating these abnormalities by either dilating the veins with a balloon or inserting a stent improves the symptoms of MS. Although some people with MS have reported improvement in their symptoms after treatment, this new theory about the cause and treatment of MS is very controversial because the quality of the science underlying it is relatively poor and the results have not been replicated by other groups. However, a number of other groups are now conducting studies, the results of which should be available over the next one to two years. The purpose of this study is to identify and summarize all of the scientific reports about CCSVI, to determine how accurately CCSVI can be diagnosed, whether or not it is more common in people with MS than in people who do not have MS, and the benefits and harms of balloon or stent treatment for CCSVI. We will use rigorous scientific methods to grade the quality of the scientific literature about this topic. We will report our initial findings in May 2011, and every 3 months after that for at least one year. We will present our findings to the CIHR expert panel on CCSVI and MS, will publish our results in scientific journals, and will also produce descriptions of our results written for people with MS, the public and health care decision makers.
Competitiondate
201201
Approvedterm2
1 yr 0 mth
Pinamesdelim
Laupacis, Andreas
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,300~ $0~